| Literature DB >> 23552809 |
Ching-Chun Lin1, Chia-Ning Huang, Jung-Der Wang, Yaw-Huei Hwang, Ruei-Hao Shie, Yu-Yin Chang, Shao-Ping Weng, Pau-Chung Chen.
Abstract
BACKGROUND: Liquid crystal display (LCD) manufacturing involves three fabrication processes: array, panel and module processes, which result in different levels of volatile organic compound (VOC) exposure. The aim of this study was to assess the potential reproductive endocrine effects of occupational exposures during LCD manufacturing predictive of menstrual cycles as subclinical markers of female reproductive dysfunction effects of low-dose exposures.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23552809 PMCID: PMC3709325 DOI: 10.3390/ijerph10041406
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Air sampling levels of volatile organic compound with potential reproductive hazards by three areas of fabrication.
| Volatile organic compounds (ppb) a | Array | Panel | Module | Regulatory Standard (ppm) | Reproductive hazard ratings b |
|---|---|---|---|---|---|
| Photo-ionization detector | |||||
| Range | 58–1472 | ND–766 | ND–21,000 | ||
| Arenes and aromatics | |||||
| Toluene | 20.8 | 7.5 | 11.1 | 100 | A+ |
| 6.9 | 1.7 | 1.1 | 100 | A− | |
| Benzene | 1.1 | 0.5 | 0.7 | 5 | A− |
| Ethylbenzene | 4.6 | 0.6 | 0.7 | B | |
| Styrene | 0.7 | ND | 0.1 | 50 | A− |
| Alkynes | |||||
| Ethanol | 281.6 | 2,256.9 | 1,974.9 | 1,000 | A+ |
| Acetone | 58.9 | 592.2 | 2,283.2 | 750 | A− |
| 2-Butanone | 4.5 | 2.9 | 3.5 | 200 | A− |
| Isopropyl alcohol | 23.8 | 4.3 | 81.0 | 400 | B− |
| Ethyl acetate | 2.6 | 1.8 | 2.0 | 400 | A+ |
| Methylene chloride | 0.9 | 1.5 | 3.5 | 50 | A+ |
| Acetaldehyde | ND | 0.6 | 1.0 | 100 | A− |
| 2-Methyl-1-propanol | ND | ND | 46.5 | B− | |
| 1-Butanol | 30.1 | ND | 10.7 | 150 | A− |
| Hexane | ND | ND | 2.9 | 50 | A− |
| 3-Methylpentane, | ND | ND | 2.1 | E | |
| 2-Methylpentane, | 1.8 | ND | 1.8 | E | |
| Methyl isobutyl ketone | 0.3 | ND | ND | 50 | E |
| 1-Methoxy-2-propyl acetate | 130.8 | ND | ND | C | |
| 1-Methoxy-2-propanol, | 36.9 | ND | ND | B− |
a Analyzed by GC-MS from 24 h canister sampling; b Reproductive hazard ratings from Microdex (REPROTOX® system): A+, human reproductive hazard with no known no-effect dose; A, human reproductive hazard with known no-effect dose; A−, unconfirmed human reproductive hazard; B+, multiple reproductive effects in animals but no human data; B, mixed reproductive effects in animals but no human data; B−, few reproductive effects in animals but no human data; C, no reproductive data found; D, insufficient information to identify; E, known not to affect animal reproduction but no human data; and F, known not to affect human reproduction.
Distributions of demographic and life style characteristics in female workers by three areas of fabrication.
| Characteristics | Array | Panel | Module | |
|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | ||
| Number included | 23 (100.0) | 53 (100.0) | 18 (100.0) | |
| Age (years) | ||||
| <30 | 12 (52.2) | 22 (41.5) | 4 (22.2) | |
| 30–44 | 10 (43.5) | 31 (58.5) | 13 (72.2) | |
| ≥45 | 1 (4.3) | 0 (0.0) | 1 (5.6) | |
| Body mass index (kg/m2) | ||||
| <18.5 | 7 (30.4) | 11 (20.8) | 4 (22.2) | |
| 18.5–24.9 | 13 (56.5) | 31 (58.5) | 9 (50.0) | |
| ≥25.0 | 3 (13.0) | 11 (20.8) | 5 (27.8) | |
| Education (years) | ||||
| <12 | 17 (73.9) | 49 (92.5) | 17 (94.4) | |
| ≥12 | 6 (26.1) | 4 (7.5) | 1 (5.6) | |
| Current smoking | ||||
| Yes | 2 (8.7) | 5 (9.4) | 1 (5.6) | |
| No | 21 (91.3) | 48 (90.6) | 17 (94.4) | |
| Current alcohol drinking | ||||
| Yes | 1 (4.3) | 2 (3.8) | 1 (5.6) | |
| No | 22 (95.7) | 51 (96.2) | 17 (94.4) | |
| Current coffee drinking | ||||
| Yes | 13 (56.6) | 16 (30.2) | 10 (55.6) | |
| No | 10 (43.5) | 37 (69.8) | 8 (44.4) | |
| Working pattern | ||||
| Regular day work | 20 (87.0) | 44 (83.0) | 12 (66.7) | |
| 12 h shift work | 3 (13.0) | 9 (17.0) | 6 (33.3) | |
| Psychosocial score a | ||||
| Low (0) | 17 (73.9) | 44 (83.0) | 17 (94.4) | |
| Middle (1–3) | 6 (26.1) | 9 (17.0) | 0 (0.0) | |
| High (≥4) | 0 (0.0) | 0 (0.0) | 1 (5.6) | |
a Based on the Chinese Health Questionnaire [9].
The mean concentrations of reproductive hormones by three areas of fabrication.
| Reproductive hormones | Array | Panel | Module | |||||
|---|---|---|---|---|---|---|---|---|
| Urine No. | Mean (SD) | Urine No. | Mean (SD) | Urine No. | Mean (SD) | |||
| Early follicular phase b | ||||||||
| FSH (mIU/mg Cr) | 156 | 0.51 (0.42) | 393 | 0.56 (0.52) | 148 | 0.65 (0.50) | 0.005 | |
| E1C (ng/mg Cr) | 152 | 19.32 (18.20) | 386 | 13.56 (12.17) | 147 | 29.28 (30.35) | <0.001 | |
| PdG (μg/mg Cr) | 155 | 0.60 (0.87) | 386 | 0.58 (0.92) | 148 | 0.89 (1.51) | 0.01 | |
| Periovulatory phase c | ||||||||
| FSH (mIU/mg Cr) | 205 | 0.48 (0.53) | 481 | 0.56 (0.78) | 179 | 0.66 (1.49) | 0.128 | |
| E1C (ng/mg Cr) | 205 | 43.17 (48.31) | 474 | 35.04 (46.62) | 179 | 50.08 (44.18) | 0.001 | |
| PdG (μg/mg Cr) | 204 | 1.08 (1.20) | 458 | 0.98 (1.29) | 179 | 0.81 (1.09) | 0.291 | |
| Luteal phase d | ||||||||
| FSH (mIU/mg Cr) | 245 | 2.53 (2.58) | 611 | 2.77 (3.03) | 213 | 4.65 (5.66) | <0.001 | |
| E1C (ng/mg Cr) | 244 | 34.16 (24.53) | 609 | 28.30 (22.18) | 197 | 33.57 (29.17) | 0.01 | |
| PdG (μg/mg Cr) | 245 | 2.23 (1.84) | 608 | 2.26 (2.29) | 218 | 2.75 (3.51) | 0.20 | |
Cr, creatinine; E1C, estrone conjugates; FSH, follicular stimulating hormone; PdG, pregnanediol-3- glucuronide; and SD, standard deviation. a Based on ANOVA tests. b Mean hormonal concentration at cycle day 1–7. c Mean hormonal concentration at day of ovulation ±3. d Mean hormonal concentration at day of ovulation +4–10.
Associations between work areas and reproductive hormones in each phase of the menstrual cycle separately.
| Reproductive hormones | Panel
| Module
| ||||
|---|---|---|---|---|---|---|
| Crude | Adjusted a | Crude | Adjusted a | |||
| β (95% CI) | β (95% CI) | β (95% CI) | β (95% CI) | |||
| Early follicular phase | ||||||
| FSH (mIU/mg Cr) | 0.33 (−0.55, 1.21) | 0.89 (0.07, 1.71) * | 1.20 (0.12, 2.28) * | 0.85 (−0.15, 1.85) | ||
| E1C (ng/mg Cr) | −5.77 (−9.10, −2.44) *** | −4.49 (−7.90, −1.08) ** | 9.95 (9.87, 10.03) **** | 12.55 (8.49, 16.61) **** | ||
| PdG (μg/mg Cr) | 0.03 (−0.17, 0.23) | 0.004 (−0.19, 0.20) | 0.32 (0.08, 0.56) ** | 0.53 (0.29, 0.77) **** | ||
| Periovulatory phase | ||||||
| FSH (mIU/mg Cr) | 0.74 (−0.63, 2.11) | 1.06 (−0.23, 2.35) | 1.72 (0.01, 3.43) * | 1.02 (−0.59, 2.63) | ||
| E1C (ng/mg Cr) | −7.46 (−14.32, −0.60) * | −5.16 (−9.61, −0.71) * | 7.40 (−1.22, 16.02) | 11.93 (6.21, 17.65) **** | ||
| PdG (μg/mg Cr) | −0.03 (−0.23, 0.17) | 0.004 (−0.20, 0.19) | 0.32 (0.08, 0.56) ** | 0.53 (0.29, 0.77) **** | ||
| Luteal phase | ||||||
| FSH (mIU/mg Cr) | 0.25 (−0.32, 0.82) | 0.20 (−0.35, 0.75) | 2.21 (1.48, 2.94) **** | 1.48 (0.81, 2.15) **** | ||
| E1C (ng/mg Cr) | −5.80 (−9.35, −2.25) *** | −3.44 (−6.99, 0.11) | 0.59 (−3.88, 5.06) | 9.29 (4.92, 13.66) **** | ||
| PdG (μg/mg Cr) | 0.04 (−0.35, 0.43) | 0.19 (−0.30, 0.68) | 0.62 (0.13, 1.11) ** | 1.01 (0.42, 1.60) *** | ||
CI, confidence interval; Cr, creatinine; E1C, estrone conjugates; FSH, follicular stimulating hormone; and PdG, pregnanediol-3-glucuronide. a Adjusted for age, BMI, education, smoking, alcohol consumption, and working pattern. * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001.